Skip to main content
main-content

The independent medical news service

19-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan supported for pretreated HER2-mutant NSCLC

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

18-09-2021 | Oncology | News | Article

COAST points to potential of durvalumab combinations in stage III NSCLC

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

17-09-2021 | Oncology | News | Article

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

Click through to read more about this approval

15-09-2021 | Oncology | News | Article

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

14-09-2021 | Oncology | News | Article

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

13-09-2021 | Oncology | News | Article

​​​​​​​Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.